Immunogenicity and Safety of an Inactivated Non-adjuvanted A(H1N1)v Influenza Vaccine in Pregnant Women

Inclusion Criteria: * 18 years to 45 years * Pregnancy between 22 and 32 weeks of gestation * Provides written informed consent * Covered by French Social Security Exclusion Criteria: * Allergy to eggs or other components in the vaccine * History of severe reactions following previous influenza vaccines * H1N1 influenza (virologically documented) during the last 6 months * Febrile episode within one week prior to vaccination * Known HIV, HBV, HCV infection * Multiple sclerosis * History of Guillain-Barré syndrome * Organ transplant recipient * Neoplastic disease in the past 3 years * Other vaccine within 3 weeks prior to study entry or planned within the month following the last injection * Systemic corticosteroids,immunotherapy,chemotherapy * Anticoagulant treatment * Immunoglobulin or blood transfusion within the 3 months prior to enrollment in this study * History of cardiac disease * Chronic liver disease * Diabetes before pregnancy * History of premature delivery * History of eclampsia * Fetal morphologic abnormalities